{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:47:37Z","timestamp":1782920857024,"version":"3.54.5"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C1005430"],"award-info":[{"award-number":["2022R1A2C1005430"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is strongly linked to cardiovascular disease (CVD) risk. Although beta-blockers (BBs) are widely used for CVD prevention, their effectiveness and safety in CKD patients without established CVD remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nationwide cohort study using Korean health insurance data. CKD patients without established CVD between 2012 and 2015 were identified based on an estimated glomerular filtration rate (eGFR) &amp;lt; 60\u00a0ml\/min\/1.73 m2 on at least two occasions. BB users were defined as those prescribed BBs for \u22656 months. Primary outcomes were all-cause mortality and 4-point major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, stroke, and hospitalization for heart failure. A 1:2 propensity score matching was performed, and Cox proportional hazards models were applied. Subgroup analyses were also conducted by eGFR category and BB agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 9067 BB users and 17\u2009094 non-users were included. BB use was associated with increased risks of all-cause mortality (hazard ratio [HR], 2.09; 95% confidence interval [CI], 1.96\u20132.24) and MACE (HR, 1.33; 95% CI, 1.26\u20131.41). The increased risks were consistent across individual outcomes, including cardiovascular death (HR, 2.07; 95% CI, 1.66\u20132.57), myocardial infarction (HR, 1.29; 95% CI, 1.13\u20131.46), stroke (HR, 1.21; 95% CI 1.13\u20131.31), and heart failure hospitalization (HR, 1.58; 95% CI, 1.44\u20131.72). Subgroup analysis showed greater mortality risk at lower eGFR levels and a higher risk of adverse events with carvedilol compared with other BBs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among CKD patients without established CVD, BB use was associated with increased mortality and cardiovascular risk. Further studies are needed to clarify whether these associations reflect treatment effects or underlying patient risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag204","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:44:03Z","timestamp":1781178243000},"source":"Crossref","is-referenced-by-count":0,"title":["Higher cardiovascular risk observed with beta-blockers in CKD patients without prior cardiovascular disease"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5132-5452","authenticated-orcid":false,"given":"Seung Hyun","family":"Han","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Inje University Ilsan Paik Hospital , Goyang, Gyunggi ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-4565","authenticated-orcid":false,"given":"Mina","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Data Science, Hanmi Pharm. Co., Ltd , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungkuk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Data Science, Hanmi Pharm. Co., Ltd , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-0597","authenticated-orcid":false,"given":"Sang Youb","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Inje University Ilsan Paik Hospital , Goyang, Gyunggi ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026070105015309000_bib1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026070105015309000_bib2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2026070105015309000_bib3","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026070105015309000_bib4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"2026070105015309000_bib5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/01.CIR.0000065187.80707.18","article-title":"\u03b2-blockers in chronic heart failure","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"2026070105015309000_bib6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2014.04.042","article-title":"Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease","volume":"64","author":"Andersson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026070105015309000_bib7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.287.7.883","article-title":"\u03b2-blocker therapy in heart failure: scientific review","volume":"287","author":"Foody","year":"2002","journal-title":"JAMA"},{"key":"2026070105015309000_bib8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/0002-9149(94)90308-5","article-title":"Beta-blocker therapy in the cardiac arrhythmia suppression trial","volume":"74","author":"Kennedy","year":"1994","journal-title":"Am J Cardiol"},{"key":"2026070105015309000_bib9","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026070105015309000_bib10","first-page":"55","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"13","author":"Byrne","year":"2024","journal-title":"Eur Heart J"},{"key":"2026070105015309000_bib11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1681\/ASN.V115912","article-title":"Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease","volume":"11","author":"Foley","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2026070105015309000_bib12","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/j.1523-1755.2004.00552.x","article-title":"Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment","volume":"65","author":"Neumann","year":"2004","journal-title":"Kidney Int"},{"key":"2026070105015309000_bib13","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should \u03b2 blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"2026070105015309000_bib14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub5","article-title":"Beta-blockers for hypertension","volume":"2017","author":"Wiysonge","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070105015309000_bib15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cardfail.2013.01.006","article-title":"Effectiveness of \u03b2-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease","volume":"19","author":"Chang","year":"2013","journal-title":"J Card Fail"},{"key":"2026070105015309000_bib16","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1093\/ndt\/gfm950","article-title":"Beta-blockers for coronary heart disease in chronic kidney disease","volume":"23","author":"Chonchol","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026070105015309000_bib17","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1046\/j.1523-1755.2002.00636.x","article-title":"Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study","volume":"62","author":"Foley","year":"2002","journal-title":"Kidney Int"},{"key":"2026070105015309000_bib18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026070105015309000_bib19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","article-title":"Beta blockers in the management of chronic kidney disease","volume":"70","author":"Bakris","year":"2006","journal-title":"Kidney Int"},{"key":"2026070105015309000_bib20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamainternmed.2015.6102","article-title":"Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review","volume":"176","author":"Konstantinidis","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026070105015309000_bib21","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070105015309000_bib22","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1001\/archinternmed.2008.511","article-title":"Comparative effectiveness of \u03b2-blockers in elderly patients with heart failure","volume":"168","author":"Kramer","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026070105015309000_bib23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/ckj\/sfaa248","article-title":"Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis","volume":"14","author":"Wu","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026070105015309000_bib24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4078\/jrd.2021.28.3.119","article-title":"Clinical study using healthcare claims database","volume":"28","author":"Park","year":"2021","journal-title":"J Rheum Dis"},{"key":"2026070105015309000_bib25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2026070105015309000_bib26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"2026070105015309000_bib27","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","journal-title":"Kidney Int"},{"key":"2026070105015309000_bib28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.23876\/j.krcp.19.103","article-title":"Association of ambulatory blood pressure monitoring with renal outcome in patients with chronic kidney disease","volume":"39","author":"Son","year":"2020","journal-title":"Kidney Res Clin Pract"},{"key":"2026070105015309000_bib29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/15748847113089990047","article-title":"The role of sympathetic nervous system in the progression of chronic kidney disease in the era of catheter based sympathetic renal denervation","volume":"8","author":"Petras","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"2026070105015309000_bib30","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1001\/archinte.164.22.2465","article-title":"\u03b2-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality","volume":"164","author":"Abbott","year":"2004","journal-title":"Arch Intern Med"},{"key":"2026070105015309000_bib31","first-page":"20","article-title":"Beta-blocker therapy in elderly patients with renal dysfunction and heart failure","volume":"18","author":"Mart\u00ednez-Milla","year":"2021","journal-title":"J Geriatr Cardiol"},{"key":"2026070105015309000_bib32","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2026070105015309000_bib33","first-page":"409","article-title":"Risk of all-cause mortality in diabetic patients taking \u03b2-blockers","volume-title":"Mayo Clinic Proceedings","author":"Tsujimoto","year":"2018"},{"key":"2026070105015309000_bib34","doi-asserted-by":"crossref","first-page":"101566","DOI":"10.1016\/j.jacadv.2024.101566","article-title":"Beta-blockers after PCI for stable coronary artery disease and preserved left ventricular ejection fraction","volume":"4","author":"Khan","year":"2025","journal-title":"JACC Adv"},{"key":"2026070105015309000_bib35","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"2026070105015309000_bib36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"2026070105015309000_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","author":"Investigators","year":"1999","journal-title":"Lancet"},{"key":"2026070105015309000_bib38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2026070105015309000_bib39","doi-asserted-by":"publisher","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026070105015309000_bib40","first-page":"893","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"Heart Failure"},{"key":"2026070105015309000_bib41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","author":"Group NMS","year":"1981","journal-title":"N Engl J Med"},{"key":"2026070105015309000_bib42","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070105015309000_bib43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070105015309000_bib44","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","article-title":"Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials","volume":"38","author":"Thomopoulos","year":"2020","journal-title":"J Hypertens"},{"key":"2026070105015309000_bib45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4070\/kcj.2023.0209","article-title":"Beta blockers in contemporary cardiology: is it better to cast them out?","volume":"54","author":"Dar","year":"2024","journal-title":"Korean Circ J"},{"key":"2026070105015309000_bib46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11906-021-01129-6","article-title":"Autonomic cardiovascular alterations in chronic kidney disease: effects of dialysis, kidney transplantation, and renal denervation","volume":"23","author":"Quarti-Trevano","year":"2021","journal-title":"Curr Hypertens Rep"},{"key":"2026070105015309000_bib47","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026070105015309000_bib48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/archinte.1983.00350050085016","article-title":"Effects of propranolol therapy on renal function and body fluid composition","volume":"143","author":"Bauer","year":"1983","journal-title":"Arch Intern Med"},{"key":"2026070105015309000_bib49","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1016\/j.bmc.2006.02.023","article-title":"Antioxidant activity of \u03b2-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?","volume":"14","author":"Gomes","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"2026070105015309000_bib50","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"2026070105015309000_bib51","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","article-title":"Third-generation \u03b2-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action","volume":"107","author":"Kalinowski","year":"2003","journal-title":"Circulation"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag204\/68519995\/sfag204.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag204\/68519995\/sfag204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag204\/68519995\/sfag204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:09:16Z","timestamp":1782918556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag204\/8707262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag204","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,12]]},"article-number":"sfag204"}}